Elinzanetant’s safety profile appeared favorable in women
Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.